We observed that PAX2 overexpression also prevented estradiol from inducing the proliferation of luminal breast cancer cells and therefore, apart from interfering with the metastatic progression of the disease, therapeutic overexpression of PAX2 could induce cytostatic effects in pre-existing primary and metastatic breast tumours. Here, PAX2 is linked to breast cancer.